Last reviewed · How we verify

dapsone gel vehicle

Almirall, S.A. · Phase 3 active Small molecule

dapsone gel vehicle is a Sulfone antibiotic with anti-inflammatory properties Small molecule drug developed by Almirall, S.A.. It is currently in Phase 3 development for Acne vulgaris (topical gel formulation).

Dapsone is a sulfone antibiotic that inhibits bacterial dihydropteroate synthase and has anti-inflammatory properties, reducing neutrophil migration and reactive oxygen species production.

Dapsone is a sulfone antibiotic that inhibits bacterial dihydropteroate synthase and has anti-inflammatory properties, reducing neutrophil migration and reactive oxygen species production. Used for Acne vulgaris (topical gel formulation).

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namedapsone gel vehicle
SponsorAlmirall, S.A.
Drug classSulfone antibiotic with anti-inflammatory properties
TargetDihydropteroate synthase; neutrophil function modulation
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 3

Mechanism of action

Dapsone works through dual mechanisms: it inhibits folate synthesis in bacteria and has potent anti-inflammatory effects by suppressing neutrophil function and reducing the production of inflammatory mediators. In topical gel formulation, it is used to treat acne and other inflammatory skin conditions by reducing bacterial colonization and neutrophil-mediated inflammation in the skin.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about dapsone gel vehicle

What is dapsone gel vehicle?

dapsone gel vehicle is a Sulfone antibiotic with anti-inflammatory properties drug developed by Almirall, S.A., indicated for Acne vulgaris (topical gel formulation).

How does dapsone gel vehicle work?

Dapsone is a sulfone antibiotic that inhibits bacterial dihydropteroate synthase and has anti-inflammatory properties, reducing neutrophil migration and reactive oxygen species production.

What is dapsone gel vehicle used for?

dapsone gel vehicle is indicated for Acne vulgaris (topical gel formulation).

Who makes dapsone gel vehicle?

dapsone gel vehicle is developed by Almirall, S.A. (see full Almirall, S.A. pipeline at /company/almirall-s-a).

What drug class is dapsone gel vehicle in?

dapsone gel vehicle belongs to the Sulfone antibiotic with anti-inflammatory properties class. See all Sulfone antibiotic with anti-inflammatory properties drugs at /class/sulfone-antibiotic-with-anti-inflammatory-properties.

What development phase is dapsone gel vehicle in?

dapsone gel vehicle is in Phase 3.

What are the side effects of dapsone gel vehicle?

Common side effects of dapsone gel vehicle include Application site erythema, Application site dryness, Application site irritation, Oiliness/seborrhea.

What does dapsone gel vehicle target?

dapsone gel vehicle targets Dihydropteroate synthase; neutrophil function modulation and is a Sulfone antibiotic with anti-inflammatory properties.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing